Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9592373 | 0.82 | KMT2A (0.44) | KMT2AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL5097812 | 0.71 | F10 (0.40) | — | |
| SCHEMBL20176617 | 0.71 | KMT2A (0.53) | KMT2AKDM4ESMN1; SMN2MGLLFAAH | |
| SCHEMBL27135900 | 0.70 | CRBN (0.51) | KMT2ASMN1; SMN2KDM1AKCNH2KDM1B | |
| SCHEMBL17893587 | 0.68 | KMT2A (0.41) | KMT2AKDM4EKDM1AKCNH2KDM1B | |
| SCHEMBL27380911 | 0.68 | NPC1 (0.38) | KDM1AKCNH2KDM1B | |
| SCHEMBL8291690 | 0.67 | KMT2A (0.44) | KMT2AKDM4ESMN1; SMN2MGLLFAAH | |
| SCHEMBL20176820 | 0.67 | NPC1 (0.41) | KMT2ASMN1; SMN2 | |
| SCHEMBL30450132 | 0.66 | ALDH1A1 (0.49) | KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21434861 | 0.66 | HTT (0.50) | SMN1; SMN2ESRRAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | KMT2A 1689/4885KDM4E 2267/4885SMN1; SMN2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.